75N93022C00059

DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS.

National Institutes of Health · United States

This contract has been awarded. Browse open opportunities

View Source

Time Left to Bid

Awarded

AwardedOtherFederal

Basic information

Reference number: 75N93022C00059
Issuing organization: National Institutes of Health · Find award history →
Government level: Federal
Solicitation type: Other
Title: DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS.
Source: USASpending (Federal)
Source ID: usa-75N93022C00059

Details

Location: United States

Description

DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS. Awarded to: AN2 THERAPEUTICS, INC Agency: Department of Health and Human Services Sub-agency: National Institutes of Health Award type: DEFINITIVE CONTRACT

Dates

Publication: 2022/09/20 12:00:00 AM UTC
Closing date: 2027/07/31 12:00:00 AM UTC

Estimated value

$9.2M USD

Classification

Normalized category

Other

Source: USASpending (Federal)

Last updated 2026-08-21, 8:45:56 p.m.

Data refreshed every 2 hours